Rebecca Dent
National University of Singapore
H-index: 53
Asia-Singapore
Top articles of Rebecca Dent
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
The Prognostic Value of CD39 as a Marker of Tumor-Specific T Cells in Triple-Negative Breast Cancer in Asian Women | Laboratory Investigation | Jia Meng Jing Ying Tira Tan Craig Ryan Joseph Jiangfeng Ye Jeffrey Chun Tatt Lim | 2024/3/1 |
Abstract PS14-05: Safety evaluation from the KEYNOTE-522 study of neoadjuvant pembrolizumab (or placebo) plus chemotherapy followed by adjuvant pembrolizumab (or placebo) in … | Cancer Research | Javier Cortés Rebecca Dent Lajos Pusztai Heather McArthur Sherko Kuemmel | 2024/5/2 |
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522 | Annals of Oncology | L Pusztai C Denkert J O’Shaughnessy J Cortes R Dent | 2024/2/17 |
Abstract LBO1-01: Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: Updated … | Cancer Research | Peter Schmid Javier Cortés Rebecca Dent Lajos Pusztai Heather McArthur | 2024/5/2 |
Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer | Clinical Cancer Research | Tira J Tan Sarah Sammons Young-Hyuck Im Lilin She Kelly Mundy | 2024/2/16 |
Abstract PO1-20-13: TROPION-Breast04: A phase 3 study of neoadjuvant datopotamab deruxtecan (Dato-DXd)+ durvalumab followed by adjuvant durvalumab vs the standard of care in … | Cancer Research | Heather McArthur Sara Tolaney Sibylle Loibl Rebecca Dent Peter Schmid | 2024/5/2 |
First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results | Clinical Cancer Research | Peter Schmid Nicholas C Turner Carlos H Barrios Steven J Isakoff Sung-Bae Kim | 2024/2/16 |
Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer | G Curigliano R Dent H Earle S Modi P Tarantino | 2024/4/1 | |
Correction to: The Evolving Landscape of Immune Checkpoint Inhibitors and Antibody Drug Conjugates in the Treatment of Early-Stage Breast Cancer | The Oncologist | P Schmid J Cortes R Dent | 2024 |
Goals of Care Among Patients With Advanced Cancer and Their Family Caregivers in the Last Years of Life | JAMA Network Open | Semra Ozdemir Isha Chaudhry Chetna Malhotra Irene Teo Eric Andrew Finkelstein | 2024/4/1 |
Eight-Year Outcomes of Bilateral Lateral Rectus Recessions versus Unilateral Recession-Resection in Childhood Basic-Type Intermittent Exotropia | Ophthalmology | Sean P Donahue Danielle L Chandler Rui Wu Justin D Marsh Christine Law | 2024/1/1 |
Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2–breast cancer | Giuseppe Curigliano Rebecca Dent Antonio Llombart-Cussac Mark Pegram Lajos Pusztai | 2023/6/28 | |
Abstract P4-09-12: Baseline and End-of-Treatment Biomarkers in Patients With PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative … | Cancer Research | Dejan Juric Nicholas Turner Sherene Loi Fabrice Andre Stephen K Chia | 2023/3/1 |
Cross‐Ancestry Genome‐Wide Association Study Defines the Extended CYP2D6 Locus as the Principal Genetic Determinant of Endoxifen Plasma Concentrations | Clinical Pharmacology & Therapeutics | Chiea Chuen Khor Stefan Winter Natalia Sutiman Thomas E Mürdter Sylvia Chen | 2023/3 |
LBA18 Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study | Annals of Oncology | P Schmid J Cortés RA Dent L Pusztai HL McArthur | 2023/10/1 |
23P Consensus statements and expert recommendations for BRCAm breast cancer in the Asia-Pacific region (STREAM-AP) | Annals of Oncology | SC Lee YH Park C Singer J Balmaña RA Dent | 2023/11/1 |
Cross-ancestry GWAS defines the extended CYP2D6 locus as the principal genetic determinant of endoxifen plasma concentrations. | Clinical Pharmacology and Therapeutics | CC Khor S Winter N Sutiman TE Mürdter S Chen | 2023/1/11 |
4MO Homologous recombination (HR) status of platinum-responsive advanced triple-negative breast cancers (aTNBC) treated with olaparib as maintenance therapy | ESMO Open | TJY Tan S Sammons JL Fink WS Ong B Jaradi | 2023/5/1 |
Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel | Joanne Wing Yan Chiu Soo Chin Lee James Chung-man Ho Yeon Hee Park Ta-Chung Chao | 2023/10 | |
Abstract OT1-03-05: TROPION-Breast02: Phase 3, open-label, randomized study of first-line datopotamab deruxtecan versus chemotherapy in patients with locally recurrent … | Cancer Research | Rebecca Dent David W Cescon Thomas Bachelot Kyung Hae Jung Zhi-Ming Shao | 2023/3/1 |
